Search
Phathom Pharmaceuticals Inc
PHATAdd to Watchlist
5.740USD
-1.270-18.12%
Close 10-22 16:00（ET）
464.37MMarket Cap
LossP/E TTM
Phathom Pharmaceuticals Inc (PHAT) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Phathom Pharmaceuticals Inc in the past month.
Buy
4 Strong Buy
6 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
20.091USD+190.33%
PHAT Analyst Recommendation Trends
In the current month, PHAT has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PHAT average Analyst price target in the last month is 20.091.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
4
4
4
4
4
4
6
6
6
6
6
6
6
5
2
2
1
1
1
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
11
11
11
11
11
11
PHAT Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
9
17
11
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Regeneron Pharmaceuticals Inc
REGN
7
15
9
0
0
31
Financial Forecasting
Based on analysts' estimates, PHAT EPS is projected to reach -0.139 in FY2026Q3, following reported EPS of -0.210 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.38
-0.32
-0.25
-0.14
-0.05
Actual
-0.29
-0.37
-0.21
--
--
Surprise
+24.90%
-14.90%
+16.50%
--
--
FAQs
What is Phathom Pharmaceuticals Inc's expected revenue for the next quarter?
Phathom Pharmaceuticals Inc's expected revenue is 85.18M.
What is Phathom Pharmaceuticals Inc's price target?
Analysts forecast that Phathom Pharmaceuticals Inc's price target is USD 20.09, with the highest forecast at USD 29.00 and the lowest forecast at USD 10.00.
How have Phathom Pharmaceuticals IncPHAT's recent earnings per share performed?
The market expectation was USD -0.21, while Phathom Pharmaceuticals IncPHAT's earnings per share (EPS) for the previous quarter was USD -0.37. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for Phathom Pharmaceuticals Inc?
Based on the ratings of Phathom Pharmaceuticals Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.